Pharmacological Approaches to Reducing the Risk of Prostate Cancer

European Urology

Volumn 55, Issue 5, 2009, Pages 1064-1074

  Rittmaster, Roger S ^a   Fleshner, Neil E ^b   Thompson, Ian M ^c  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Dutasteride; Finasteride; PCPT; Prevention; Prostate cancer; REDUCE; Risk reduction

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DUTASTERIDE; ESTROGEN; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROFECOXIB; SELENIUM; TOREMIFENE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIGITAL RECTAL EXAMINATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; HUMAN; INCIDENCE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; AZASTEROIDS; CHEMOPREVENTION; DIET; EARLY DETECTION OF CANCER; ENZYME INHIBITORS; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 62649144537     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.037     Document Type: Review

References (42)

1. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 8 (1994) 439-443
2. Syed D.N., Khan N., Afaq F., and Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 16 (2007) 2193-2203
3. Fleshner N., and Zlotta A.R. Prostate cancer prevention: past, present, and future. Cancer 110 (2007) 1889-1899
4. Thompson I.M., and Ankerst D.P. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 176 (2007) 1853-1858
5. Johns L.E., and Houlston R.S. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 91 (2003) 789-794
6. Kote-Jarai Z., Easton D.F., Stanford J.L., et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 17 (2008) 2052-2061
7. Hsing A.W., Sakoda L.C., and Chua Jr. S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86 (2007) s843-s857
8. Crawford E.D. Epidemiology of prostate cancer. Urology 62 (2003) 3-12
9. Sutcliffe S., and Platz E.A. Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 25 (2007) 242-249
10. Nelson W.G. Prostate cancer prevention. Curr Opin Urol 17 (2007) 157-167
11. Stock D., Groome P.A., and Siemens D.R. Inflammation and prostate cancer: a future target for prevention and therapy?. Urol Clin North Am 35 (2008) 117-130 vii
12. Dehm S.M., and Tindall D.J. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 99 (2006) 333-344
13. Kumar-Sinha C., Tomlins S.A., and Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 8 (2008) 497-511
14. Prins G.S., and Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73 (2008) 233-244
15. Ricke W.A., Wang Y., and Cunha G.R. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 75 (2007) 871-882
16. Daskivich T.J., and Oh W.K. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 16 (2006) 173-178
17. Ganry O. Phytoestrogens and prostate cancer risk. Prev Med 41 (2005) 1-6
18. Tindall D.J., and Rittmaster R.S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 179 (2008) 1235-1242
19. Rittmaster R., Hahn R.G., Ray P., Shannon J.B., and Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72 (2008) 808-812
20. Eggener S.E., Stern J.A., Jain P.M., et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66 (2006) 495-502
21. Thomas L.N., Douglas R.C., Lazier C.B., et al. Type 1 and type 2 5α-reductase expression in the development and progression of prostate cancer. Eur Urol 53 (2008) 244-252
22. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride in the development of prostate cancer. N Engl J Med 349 (2003) 215-224
23. Cohen Y.C., Liu K.S., Heyden N.L., et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1366-1374
24. Thompson I.M., Chi C., Ankerst D.P., et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98 (2006) 1128-1133
25. Thompson I.M., Tangen C.M., Goodman P.J., et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 177 (2007) 1749-1752
26. Lucia M.S., Epstein J.I., Goodman P.J., et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1375-1383
27. Pinsky P., Parnes H., and Ford L. Estimating rates of true high-grade disease in the Prostate Cancer Prevention Trial. Cancer Prev Res 1 (2008) 182-186
28. Redman M.W., Tangen C.M., Goodman P.J., Lucia M.S., Coltman Jr. C.A., and Thompson I.M. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 1 (2008) 182-186
29. Moinpour C.M., Darke A.K., Donaldson G.W., et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99 (2007) 1025-1035
30. Svatek R.S., Lee J.J., Roehrborn C.G., Lippman S.M., and Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 112 (2008) 1058-1065
31. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Am Med Assoc 301 (2009) 39-51
32. Andriole G.L., Roehrborn C., Schulman C., et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
33. Gleave M., Qian J., Andreou C., et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 66 (2006) 1674-1685
34. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314-1317
35. Fleshner N., Gomella L.G., Cookson M.S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 28 (2007) 763-769
36. Hamilton R.J., and Freedland S.J. Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Curr Opin Urol 18 (2008) 333-339
37. Platz E.A., Leitzmann M.F., Visvanathan K., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98 (2006) 1819-1825
38. Pruthi R.S., Derksen E., and Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169 (2003) 2352-2359
39. Hussain T., Gupta S., and Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191 (2003) 125-135
40. Raghow S., Hooshdaran M.Z., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 62 (2002) 1370-1376
41. Price D., Stein B., Sieber P., et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 176 (2006) 965-970 discussion 970-1
42. Schroder F.H., Roobol M.J., Andriole G., and Fleshner N. Defining men at increased future risk of prostate cancer: evidence from a population-based screening cohort. J Urol 181 (2009) 69-74